HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Meta-Analysis Comparing Dual Versus Single Antiplatelet Therapy in Combination With Antithrombotic Therapy in Patients With Atrial Fibrillation Who Underwent Percutaneous Coronary Intervention With Stent Implantation.

Abstract
The coexistence of atrial fibrillation and coronary artery disease is commonly found in clinical practice. The aim of this meta-analysis is to compare the clinical efficacy and safety of dual versus single antiplatelet therapy in combination with antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. PubMed, EMBASE and Web of Science databases were systematically evaluated for articles published up to October 31, 2017. The risk ratios (RR) were extracted from each study. Pooled estimates with corresponding 95% confidence intervals (CI) were estimated by a fixed or random-effects model. Eight studies involving a total of 10,861 patients with atrial fibrillation were included in this meta-analysis. Five thousand sixty-six participants received dual antiplatelet therapy together with warfarin or new oral anticoagulation (triple antithrombotic therapy, TT) and 5,795 participants received single antiplatelet therapy together with warfarin or new oral anticoagulation (dual antithrombotic therapy). TT was associated with a significantly higher incidence of all (RR 1.45, p <0.001) and major (RR 1.77, p <0.001) bleeding events, but no difference with regard to stroke, in-stent thrombosis, major adverse cardiovascular events, and all-cause mortality rate. In conclusion, as compared to TT, dual antithrombotic therapy is equally effective in reducing stroke, in-stent thrombosis, major adverse cardiovascular events, and all-cause mortality rate, but shows beneficial effect in reducing overall bleeding incidence in atrial fibrillation patients who underwent percutaneous coronary intervention.
AuthorsBowen Lou, Xiao Liang, Yue Wu, Yangyang Deng, Bo Zhou, Zuyi Yuan, Jianqing She
JournalThe American journal of cardiology (Am J Cardiol) Vol. 122 Issue 4 Pg. 604-611 (08 15 2018) ISSN: 1879-1913 [Electronic] United States
PMID30205887 (Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Review)
CopyrightCopyright © 2018 The Author(s). Published by Elsevier Inc. All rights reserved.
Chemical References
  • Fibrinolytic Agents
  • Platelet Aggregation Inhibitors
Topics
  • Atrial Fibrillation (complications, drug therapy)
  • Coronary Artery Disease (complications, surgery)
  • Drug Therapy, Combination
  • Fibrinolytic Agents (therapeutic use)
  • Humans
  • Percutaneous Coronary Intervention (adverse effects)
  • Platelet Aggregation Inhibitors (therapeutic use)
  • Postoperative Complications (prevention & control)
  • Stents
  • Thrombosis (prevention & control)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: